Conference paper

THE ROLE OF ANTI-INFLAMMATORY TREATMENT IN PSYCHIATRIC DISORDERS

Norbert Müller ; Department of Psychiatry and Psychotherapy, Ludwig-Maximilian University Munich, Munich, Germany

Abstract

Anti-inflammatory treatment could be expected to show positive effects in the subgroup of psychiatric patients who show signs of
inflammation, i.e. an increase in proinflammatory cytokines and PGE2. Cyclooxygenase-2 (COX-2) not only reduces the levels of
proinflammatory cytokines, but also affects glutamatergic neurotransmission and tryptophan/kynurenine metabolism. In the
meantime, several studies have been performed with the COX-2 inhibitor celecoxib in schizophrenia; the studies found a therapeutic
effect, mainly in the early stages of the disorder. We were able to demonstrate a statistically significant therapeutic effect of
celecoxib on depressive symptoms in a study in patients with major depression (MD). Another study in fifty patients with MD also
showed a statistically significant better outcome with celecoxib.
This paper will discuss immune-based therapeutic approaches in both schizophrenia and depression.

Keywords

inflammation – schizophrenia - major depression – treatment - COX-2 inhibition

Hrčak ID:

161209

URI

https://hrcak.srce.hr/161209

Publication date:

17.9.2013.

Visits: 949 *